Proximity-based drug discovery opens up a whole new universe of “undruggable” targets. From PROTACs and molecular glues to next-gen degraders and stabilisers, the field is moving fast from promise to clinical reality - with improved safety, drug-like properties, and broader application beyond oncology.
Now in its sixth year, this Europe-focused summit is the only forum dedicated entirely to targeted protein degradation and induced proximity. The agenda encompasses rational design, oral bioavailability, PK/PD modeling, and clinical translation, with real-world insights into oncology, immunology, neurodegeneration, and rare diseases.
Download the agenda to explore first-in-human data, biology-led strategies, and emerging degradation platforms shaping the future of proximity therapeutics – and see how Europe’s biopharma leaders are accelerating these modalities from discovery to clinic.
About Hanson Wade Group - 6th TPD & Induced Proximity Summit Europe
Progressing PROTACS, Molecular Glues, & Emerging Proximity Therapeutics to the Clinic with Improved Safety & Drug Properties to Target Undruggables in Oncology & Beyond.
The 6th TPD & Induced Proximity Summit Europe is the only European forum dedicated exclusively to proximity-based drug discovery. From PROTACs and molecular glues to stabilizers and extracellular degraders, this summit showcases the full spectrum of therapeutic innovation across oncology, neurodegeneration, immunology, and rare diseases. Held in London in March 2026, the event brings together more than 80 CxOs, directors, senior scientists, and investors to accelerate proximity therapeutics from discovery to clinic.
Europe is experiencing a surge in strategic investment and innovation, including Sanofi’s acquisition of Blueprint Medicines for £7.2 billion and Merck’s £2.7 billion purchase of SpringWorks Therapeutics. As the region pivots toward non-oncology indications and novel mechanisms, drug developers face challenges in rational design, oral bioavailability, PK and PD modelling, and clinical translation.
This summit addresses those challenges with insights from leading companies, including GSK, AbbVie, Amphista, Autotac Bio, PhoreMost, Laigo Bio, and Foghorn Therapeutics. Attendees will gain access to first-in-human data, biology-first strategies, and novel degradation platforms that are redefining the druggable proteome.
Whether you are advancing early discovery or preparing clinical candidates, this is your opportunity to connect with Europe's most innovative biopharma teams and stay ahead in the evolving induced proximity landscape.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.